MedTrace Logo

Dose-finding Study for the Combination of DMT and Harmine in Healthy Subjects

NCT05829603 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 16

Last updated 2023-11-02

No results posted yet for this study

Summary

The goal of this clinical trial is to compare corresponding inter- and intraindividual pharmacokinetic and pharmacodynamic profiles including assessments of safety \& tolerability.

Conditions

  • Healthy

Interventions

DRUG

Dimethyltryptamin (DMT) & Harmine

Six varying doses of a fixed-combination formulation of Dimethyltryptamin (DMT) and harmine

Sponsors & Collaborators

  • Reconnect Labs

    lead INDUSTRY

Principal Investigators

  • Erich Seifritz, Prof · University Hospital of Psychiatry Zurich

Study Design

Allocation
RANDOMIZED
Purpose
OTHER
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
25 Years
Max Age
45 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2023-05-05
Primary Completion
2023-09-17
Completion
2023-10-17

Countries

  • Switzerland

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05829603 on ClinicalTrials.gov